IXCHIQ is the first single-dose vaccine approved to help prevent ...
IXCHIQ is a vaccine indicated for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 18 years of age and older who are at increased risk of exposure to CHIKV. This indication is approved under accelerated approval based …
Chikungunya Vaccine Information for Healthcare Providers
Jan 30, 2025 · A live attenuated chikungunya vaccine (manufactured by Valneva as IXCHIQ) is the only chikungunya vaccine currently licensed in the United States. This vaccine was approved by the Food and Drug Administration (FDA) in November 2023.
IXCHIQ | FDA
Jan 10, 2024 · For the prevention of disease caused by chikungunya virus (CHIKV) in individuals 18 years of age and older who are at high risk of exposure to CHIKV.
FDA Approves First Vaccine to Prevent Disease Caused by …
The FDA approved Ixchiq, the first vaccine for prevention of disease caused by chikungunya virus in individuals 18 years of age and older who are at increased risk of exposure to...
Chikungunya Vaccine | Chikungunya Virus | CDC
One chikungunya vaccine (called IXCHIQ) is available in the United States. Some travelers at higher risk of exposure to chikungunya virus or at increased risk of severe disease should consider this vaccine.
Ixchiq: Uses, Dosage, Side Effects, Warnings - Drugs.com
Mar 26, 2024 · What is Ixchiq? Ixchiq is a chikungunya virus vaccine used to prevent chikungunya disease. Ixchiq contains a live, weakened version of the chikungunya virus that helps build up an immune response to the chikungunya virus to prevent potentially debilitating chikungunya disease if you get the chikungunya virus in the future.
Chikungunya Vaccine – IXCHIQ® - Valneva
The chikungunya vaccine IXCHIQ® is the world’s first and only licensed chikungunya vaccine available to address this significant unmet medical need. IXCHIQ® is approved in the United States, Canada and Europe.
FDA Approves First Vaccine to Prevent Disease Caused by …
SILVER SPRING, Md., Nov. 9, 2023 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Ixchiq, the first chikungunya vaccine. Ixchiq is approved for individuals 18 years of age...
Home - Ixchiq
IXCHIQ™ is a vaccine for intramuscular injection for use in individuals 18 years of age and older to help protect against chikungunya virus. As with all vaccines, 100% protection is not guaranteed. IXCHIQ™ does not treat an infection or its complications once they develop.
Ixchiq - European Medicines Agency (EMA)
Ixchiq contains a strain of chikungunya virus that has been attenuated (weakened) so that it does not cause disease. When a person is given Ixchiq, the immune system recognises the weakened virus as ‘foreign’ and makes antibodies against it.